These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22160853)

  • 21. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
    Bahleda R; Grilley-Olson JE; Govindan R; Barlesi F; Greillier L; Perol M; Ray-Coquard I; Strumberg D; Schultheis B; Dy GK; Zalcman G; Weiss GJ; Walter AO; Kornacker M; Rajagopalan P; Henderson D; Nogai H; Ocker M; Soria JC
    Br J Cancer; 2017 Jun; 116(12):1505-1512. PubMed ID: 28463960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.
    Sun Y; Niu W; Du F; Du C; Li S; Wang J; Li L; Wang F; Hao Y; Li C; Chi Y
    J Hematol Oncol; 2016 Oct; 9(1):105. PubMed ID: 27716285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.
    Schöffski P; Aftimos P; Dumez H; Deleporte A; De Block K; Costermans J; Billiet M; Meeus MA; Lee C; Schnell D; Goeldner RG; Awada A
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):99-108. PubMed ID: 26650227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
    Venkatakrishnan K; Kim TM; Lin CC; Thye LS; Chng WJ; Ma B; Chen MH; Zhou X; Liu H; Kelly V; Kim WS
    Invest New Drugs; 2015 Aug; 33(4):942-53. PubMed ID: 26084989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
    Falchook GS; Kurzrock R; Amin HM; Xiong W; Fu S; Piha-Paul SA; Janku F; Eskandari G; Catenacci DV; Klevesath M; Bruns R; Stammberger U; Johne A; Bladt F; Friese-Hamim M; Girard P; El Bawab S; Hong DS
    Clin Cancer Res; 2020 Mar; 26(6):1237-1246. PubMed ID: 31822497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
    Do KT; O'Sullivan Coyne G; Hays JL; Supko JG; Liu SV; Beebe K; Neckers L; Trepel JB; Lee MJ; Smyth T; Gannon C; Hedglin J; Muzikansky A; Campos S; Lyons J; Ivy P; Doroshow JH; Chen AP; Shapiro GI
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):815-827. PubMed ID: 33095286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
    Bendell JC; Bischoff HG; Hwang J; Reinhardt HC; Zander T; Wang X; Hynes S; Pitou C; Campbell R; Iversen P; Farrington DL; Bell-McGuinn K; Thomas M
    Invest New Drugs; 2020 Aug; 38(4):1145-1155. PubMed ID: 31707688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.
    van Bussel MTJ; Awada A; de Jonge MJA; Mau-Sørensen M; Nielsen D; Schöffski P; Verheul HMW; Sarholz B; Berghoff K; El Bawab S; Kuipers M; Damstrup L; Diaz-Padilla I; Schellens JHM
    Br J Cancer; 2021 Feb; 124(4):728-735. PubMed ID: 33230210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors.
    Kim TM; Lee KW; Oh DY; Lee JS; Im SA; Kim DW; Han SW; Kim YJ; Kim TY; Kim JH; Han H; Kim WH; Bang YJ
    Cancer Res Treat; 2018 Jul; 50(3):835-842. PubMed ID: 28859471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
    Boss DS; Schwartz GK; Middleton MR; Amakye DD; Swaisland H; Midgley RS; Ranson M; Danson S; Calvert H; Plummer R; Morris C; Carvajal RD; Chirieac LR; Schellens JHM; Shapiro GI
    Ann Oncol; 2010 Apr; 21(4):884-894. PubMed ID: 19825886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
    Weiss GJ; Jameson G; Von Hoff DD; Valsasina B; Davite C; Di Giulio C; Fiorentini F; Alzani R; Carpinelli P; Di Sanzo A; Galvani A; Isacchi A; Ramanathan RK
    Invest New Drugs; 2018 Feb; 36(1):85-95. PubMed ID: 28726132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
    Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
    Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
    Jänne PA; Boss DS; Camidge DR; Britten CD; Engelman JA; Garon EB; Guo F; Wong S; Liang J; Letrent S; Millham R; Taylor I; Eckhardt SG; Schellens JH
    Clin Cancer Res; 2011 Mar; 17(5):1131-9. PubMed ID: 21220471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
    Mita MM; Mita AC; Moseley JL; Poon J; Small KA; Jou YM; Kirschmeier P; Zhang D; Zhu Y; Statkevich P; Sankhala KK; Sarantopoulos J; Cleary JM; Chirieac LR; Rodig SJ; Bannerji R; Shapiro GI
    Br J Cancer; 2017 Oct; 117(9):1258-1268. PubMed ID: 28859059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
    Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
    Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
    Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
    Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors.
    Papadopoulos KP; Borazanci E; Shaw AT; Katayama R; Shimizu Y; Zhu VW; Sun TY; Wakelee HA; Madison R; Schrock AB; Senaldi G; Nakao N; Hanzawa H; Tachibana M; Isoyama T; Nakamaru K; Deng C; Li M; Fan F; Zhao Q; Gao Y; Seto T; Jänne PA; Ou SI
    Clin Cancer Res; 2020 Sep; 26(18):4785-4794. PubMed ID: 32591465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).
    Schwartz GK; LoRusso PM; Dickson MA; Randolph SS; Shaik MN; Wilner KD; Courtney R; O'Dwyer PJ
    Br J Cancer; 2011 Jun; 104(12):1862-8. PubMed ID: 21610706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
    Leijen S; Middleton MR; Tresca P; Kraeber-Bodéré F; Dieras V; Scheulen ME; Gupta A; Lopez-Valverde V; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Schellens JH; Eberhardt WE
    Clin Cancer Res; 2012 Sep; 18(17):4794-805. PubMed ID: 22767668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.